



**HAL**  
open science

## Differential Metabolic Sensitivity of mTORC1-and mTORC2-Dependent Overgrowth

Maëlle Devilliers, Damien Garrido, Mickaël Poidevin, Thomas Rubin, Arnaud  
Le Rouzic, Jacques Montagne

► **To cite this version:**

Maëlle Devilliers, Damien Garrido, Mickaël Poidevin, Thomas Rubin, Arnaud Le Rouzic, et al.. Differential Metabolic Sensitivity of mTORC1-and mTORC2-Dependent Overgrowth. 2019. hal-02155216

**HAL Id: hal-02155216**

**<https://hal.science/hal-02155216>**

Preprint submitted on 13 Jun 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



23 **ABSTRACT**

24 The protein kinase mTOR is implicated in metabolic-related diseases and chiefly controls  
25 organismal growth and homeostasis in response to nutrients. Activation of mTOR promotes cell  
26 growth and enhances a glycolytic/lipogenic axis, suggesting that this metabolic axis is required  
27 to sustain mTOR-dependent growth. Here, we used *Drosophila* genetics to investigate this  
28 functional link both at the organismal and cell-autonomous levels. mTOR is present in two  
29 distinct complexes mTORC1 and mTORC2, which can be independently modulated in most  
30 *Drosophila* tissues. We confirm this independency in the fat body, the organ that fulfils hepatic  
31 and adipose functions. We show that ubiquitous mTOR over-activation affects carbohydrate and  
32 lipid metabolism, supporting the use of *Drosophila* as a powerful model to study the link  
33 between mTOR and metabolism. We show that targeted glycolytic or lipogenic restriction in fat  
34 body cells exclusively impedes mTORC2-induced overgrowth. Additionally, ubiquitous  
35 deficiency of lipogenesis (*FASN* mutants) results in a drop in mTORC1 but not mTORC2  
36 signaling, whereas, at the cell-autonomous level, lipogenesis deficiency in fat body cells affects  
37 neither mTORC1 nor mTORC2 activity. These findings thus, reveal differential metabolic  
38 sensitivity of mTORC1- and mTORC2-dependent overgrowth. Furthermore, they suggest that  
39 local metabolic defects may elicit compensatory pathways between neighboring cells, whereas  
40 enzyme knockdown in the whole organism results in animal death. Importantly, our study  
41 weakens the use of single inhibitors to fight mTOR-related diseases and strengthens the use of  
42 drug combination and selective tissue-targeting.

#### 44 **AUTHOR SUMMARY**

45 Cell growth is essential for animal development but is also deregulated in several human  
46 diseases including cancers. The mTOR signaling network controls cell growth in response to  
47 nutrients and growth factors. mTOR stimulation has been shown to promote basal metabolism,  
48 including the glycolytic/lipogenic axis, which is essential to provide energetic cofactors and  
49 building blocks to sustain cell growth. However, the requirement this metabolic axis for mTOR-  
50 dependent growth has been poorly investigated yet. To address this issue, we used *Drosophila*  
51 genetics and focused on the fat tissue that fulfils hepatic and adipose functions. Surprisingly, in  
52 mosaic animals, where only a few cells were genetically stimulated for mTOR, we observed that  
53 metabolic knockdown only moderates cell overgrowth. Additionally, this growth restriction  
54 operates for only one of the two mTOR signaling branches, suggesting that mTOR-dependent  
55 compensatory processes operate to circumvent metabolic defects. Given that ubiquitous  
56 knockdown of this metabolic axis is essential for juvenile development and adult survival, our  
57 study reveals that metabolic restriction is unlikely sufficient to counteract overgrowth disorders.

## 59 INTRODUCTION

60 Growth of a multicellular organism is coordinated by signaling pathways that adjust intracellular  
61 processes to environmental changes. These signaling pathways include the mTOR  
62 (mechanistic Target Of Rapamycin) regulatory network that integrates the growth factor  
63 response as well as the nutritional and energetic status [1-7]. This network consists in two  
64 signaling branches in which the mTOR protein kinase is present in two distinct complexes,  
65 mTORC1 and mTORC2 that comprise raptor and rictor, respectively [8, 9]. Both mTORC1 and  
66 mTORC2 promote basal cellular functions, thereby providing building blocks to sustain cellular  
67 growth. However, despite a plethora of studies on mTORC1/2 signaling and functions, the  
68 requirement of basal metabolism—glycolytic/lipogenic axis— for mTOR-dependent cell growth  
69 has not been systematically investigated. The *Drosophila* model provides a powerful genetic  
70 system to address these issues [10], since both the intermediates of the mTOR signaling  
71 network and the basal metabolic pathways are conserved in the fruit fly [11-15].

72 Regulation of mTORC1 activity by ATP and amino acids depends on a multi-step process that  
73 results in the recruitment of an mTORC1 homodimer at the lysosomal membrane in the vicinity  
74 of the small GTPase Rheb (Ras homologue enriched in brain) [16-20]. Rheb stimulates  
75 mTORC1 activity [21], which in turn regulates several downstream targets. S6Kinase1 (S6K1) is  
76 one such kinase, sequentially activated through the phosphorylation of its T389 and T229  
77 residues by mTORC1 and by PDK1 (Phosphoinositide-dependent protein kinase 1),  
78 respectively [22, 23]. Further, Rheb activation of mTORC1 is repressed by the tumor suppressor  
79 TSC (Tuberous sclerosis complex) that comprises subunits TSC1 and TSC2 [24-27].

80 The mTORC2 branch resides within the insulin signaling cascade [9]. Binding of insulin or  
81 related peptides to their cognate receptors results in recruitment of class I PI3K  
82 (Phosphoinositide 3-kinase) to the membrane. PI3K phosphorylates inositol lipids producing  
83 phosphatidylinositol-3,4,5-triphosphate (PIP3) [28, 29], while the tumor suppressor PTEN acts  
84 as a lipid phosphatase to counteract this process [30]. PIP3 constitutes a membrane docking

85 site for the protein kinase Akt whose subsequent activation depends on the phosphorylation of  
86 its S473 and T308 residues by mTORC2 and PDK1, respectively [31].

87 Constitutive activation of mTORC1 in MEFs (Mouse embryonic fibroblasts) has been shown to  
88 stimulate a metabolic network, including glycolysis, the pentose phosphate pathway and the  
89 biosynthesis of fatty acid (FA) and cholesterol [32]. Most of the genes encoding glycolytic  
90 enzymes are over-expressed in these cells as are those encoding LDH (lactate dehydrogenase)  
91 and Pdk1 (Pyruvate dehydrogenase kinase 1; an inhibitor of mitochondrial pyruvate  
92 processing). This suggests that mTORC1-activated MEFs potentiate anaerobic glycolysis and  
93 repress the tricarboxylic acid cycle (TCA). Conversely, adipose-specific knockout of raptor to  
94 impede mTORC1 formation, results in enhanced uncoupling of mitochondrial activity [33]. The  
95 increased lipogenesis observed in mTORC1 stimulated cells depends on a downstream  
96 transcriptional regulatory axis involving the cofactor Lipin 1 along with a SREBP (Sterol  
97 responsive element binding-protein) family member, which activates genes encoding lipogenic  
98 enzymes [32, 34]. Congruently, another study revealed that TSC2 mutant cells become  
99 addicted to glucose as a result of mTORC1 hyper-activity [35]. In addition, inhibition of mTORC1  
100 activity revealed that these TSC2 mutant cells become also dependent on glutamine catabolism  
101 [36]; mTORC1 potentiates this catabolism to feed TCA anaplerosis, through 1) a  
102 S6K/eIF4B/Myc axis that increases glutaminase protein levels [37] and 2) the repression of  
103 SIRT4, a mitochondrial sirtuin that inhibits glutamine dehydrogenase [38].

104 Besides mTORC1 mediated regulation, mTORC2 also impinges on basal metabolism.  
105 Intracellular activation of Akt increases ATP levels [39, 40] through the stimulation of GLUT4-  
106 mediated glucose uptake [41] and the enhancement of the expression and activity of glycolytic  
107 enzymes [42, 43]. Akt also dampens glucose production by suppressing PEPCK  
108 (gluconeogenesis), glucose-6-phosphatase (glycogenolyse) and the glycogen synthesis  
109 repressor GSK3 [44, 45]. However, in contrast to mTORC1, Akt also promotes mitochondrial  
110 metabolism and oxidative phosphorylations [42, 46]. Conversely, hepatic knockout of the  
111 mTORC2 specific-subunit rictor results in constitutive gluconeogenesis and impaired glycolysis

112 and lipogenesis [47, 48]. Taken together, these studies strongly emphasize the role of mTOR in  
113 metabolic-related diseases and in adjusting metabolism to the nutritional and energetic status  
114 [7].

115 In the present study, we investigated the requirement of the glycolytic/lipogenic axis for the  
116 cellular growth induced by mTORC1 and mTORC2 hyper-activation in *Drosophila*. As previously  
117 demonstrated mTORC1 and mTORC2 reside on independent signaling branches in most  
118 *Drosophila* tissues [24, 49-52]. Here, we confirmed mTORC1 and 2 independency in the fat  
119 body (FB), the organ that fulfils hepatic and adipose functions to control body homeostasis in  
120 *Drosophila* [12, 13, 15]. We analyzed the effect of ubiquitous mTOR activation on glycolysis and  
121 lipogenesis. We show that an increase in mTOR activity provokes an apparent enhancement of  
122 metabolite consumption. Furthermore, our study reveals that metabolic restriction at the  
123 organismal level has dramatic consequences on animal survival, but no effect at the cell-  
124 autonomous level, suggesting that within an organism, alternative pathways may operate to  
125 compensate local metabolic defects. Nonetheless, at the cell-autonomous level, metabolic  
126 restriction can restrain mTORC2- but not mTORC1-induced overgrowth, indicating that the  
127 potential compensatory metabolic pathways do not fully operate in the context of mTORC2  
128 over-activation.

129

## 130 **RESULTS**

### 131 **mTORC1 and mTORC2 independency in the fat body**

132 Previous studies showed that mTORC1 and mTORC2 reside on independent signaling  
133 branches in most *Drosophila* tissues [24, 49-52]. Activating either the mTORC1 or the mTORC2  
134 signaling branch can be performed by overexpressing Rheb or depleting PTEN, respectively. To  
135 investigate mTORC1/2 independency in the FB, we generated somatic clones either over-  
136 expressing Rheb (*Rheb*<sup>+</sup>) [53] or homozygote for a *PTEN* mutation (*PTEN*<sup>-/-</sup>) [54]. The  
137 precursors of FB cells divide in the embryo; during larval life, the differentiated cells do not

138 divide but endoreplicate their DNA content to reach a giant size [55]. Therefore, to precisely  
139 evaluate the effect on cell growth, somatic recombination events were induced during  
140 embryogenesis at the stage of proliferation of the FB cell precursors and the resulting MARCM  
141 clones were analyzed in the FB of late feeding L3 larvae, prior to the wandering stage that  
142 precedes metamorphosis entry. Both *PTEN*<sup>-/-</sup> and *Rheb*<sup>+</sup> clonal cells were bigger than the  
143 surrounding control cells and this cell size effect was dramatically increased in *PTEN*<sup>-/-</sup>;*Rheb*<sup>+</sup>  
144 combined clones (Figure 1A-D and 1M). We next analyzed this growth increase in the context of  
145 the previously described *mTOR*<sup>2L1</sup> and *mTOR*<sup>ΔP</sup> mutations. However, we could not find mutant  
146 clones in the FB. Consistent with previous studies reporting that mTOR is critically required for  
147 cell growth of endoreplicative tissues [54, 56], we reasoned that these clonal cells were likely  
148 eliminated by cell competition [57]. Thus, we generated somatic clones in a *Minute* background  
149 to slow down the growth of the surrounding control cells. In these conditions, *mTOR* mutant  
150 clones could indeed be recovered. Both *mTOR*<sup>2L1</sup> and *mTOR*<sup>ΔP</sup> mutant cells exhibited a  
151 dramatic size reduction (Figure 1G and 1J) and this phenotype was dominant in *Rheb*<sup>+</sup>  
152 combined clonal cells (compare Figure 1E to 1H and 1K). In contrast, *mTOR*<sup>ΔP</sup> but not *mTOR*<sup>2L1</sup>  
153 exhibited a clear dominant phenotype over the *PTEN*<sup>-/-</sup> mutation; the size of *mTOR*<sup>ΔP</sup>,*PTEN*<sup>-/-</sup>  
154 clonal cells was dramatically reduced, whereas *mTOR*<sup>2L1</sup>,*PTEN*<sup>-/-</sup> clonal cells were giant  
155 (compare Figure 1F to 1I and 1L). These findings indicate that the *mTOR*<sup>2L1</sup> mutation affects  
156 mTORC1 but not mTORC2 signaling, whereas *mTOR*<sup>ΔP</sup> affects both signaling branches.

157 Next, we used phospho-specific antibodies in immunostaining assays to analyze the  
158 phosphorylation of Akt (P-Akt) and of the dS6K target, ribosomal protein rpS6 (P-S6). In *PTEN*<sup>-/-</sup>  
159 clonal cells, we observed an increase in the P-Akt intracellular signal (Figure 2A). Importantly  
160 the P-Akt intracellular signal was absent in *mTOR*<sup>ΔP</sup> cells (Figure 2B) but not affected in  
161 *mTOR*<sup>2L1</sup> cells (Figure 2C). Staining with the rpS6 phospho-specific antibody revealed a patchy  
162 signal, with only a subset of cells expressing the P-S6 signal in the FB (Figure 2E-J), a pattern  
163 previously described in the wing imaginal disc [58]. Therefore, to evaluate mTORC1 activity, we  
164 measured the ratio of P-S6 positive cells among the population of GFP<sup>+</sup> clonal cells. For control



165 clones, only labeled by GFP, about half of them were P-S6 positive (Figure 2E and 2K),  
166 whereas most of the *mTOR<sup>2L1</sup>* and *mTOR<sup>ΔP</sup>* clones were P-S6 negative (Figure 2F, 2G and 2K).  
167 Importantly, almost all the *Rheb<sup>+</sup>* cells were P-S6 positive (Figure 2H and 2K), whereas the ratio  
168 of P-S6 positive cells was slightly but not significantly increased in the *PTEN<sup>-/-</sup>* cell population  
169 (Figure 2I and 2K). Taken together, these findings confirm that mTORC1 and mTORC2 operate  
170 independently in FB cells and reveal that the *mTOR<sup>2L1</sup>* mutation affects only mTORC1, whereas  
171 the *mTOR<sup>ΔP</sup>* mutation affects both signaling branches.

172

### 173 **Activating mTORC1 or mTORC2 signaling impacts basal metabolism**

174 A number of studies support the notion that mTOR activity controls metabolism to sustain  
175 cellular growth. To evaluate how mTORC1 and mTORC2 affect basal metabolism in *Drosophila*,  
176 we analyzed various metabolites in whole animals that express the ubiquitous *da-gal4* driver to  
177 direct Rheb overexpression (*Rheb<sup>++</sup>*) or PTEN knockdown by RNA interference (*PTEN-RNAi*).  
178 Larvae were fed either a standard or a 20%-sucrose supplemented diet (20%-SSD) and 0-5h  
179 prepupae were collected, as this is a convenient phase to stage the animals after the feeding  
180 period. When fed a standard diet, a high rate of lethality was observed for *Rheb<sup>++</sup>* and *PTEN-*  
181 *RNAi* larvae, although a sufficient number of prepupae could be collected for metabolic analysis.  
182 In contrast, none of the *Rheb<sup>++</sup>* and *PTEN-RNAi* larvae reached the prepupal stage when fed a  
183 20%-SSD. Nonetheless, when *Rheb<sup>++</sup>* and *PTEN-RNAi* larvae were fed a standard diet during  
184 early larval life and transferred onto a 20%-SSD at the L2/L3 molting transition, we could  
185 recover a few prepupae for metabolic measurements. For both males and females fed a  
186 standard diet, the body weight of *Rheb<sup>++</sup>* and *PTEN-RNAi* prepupae was roughly similar to that  
187 of controls (Figure 3A and 3B). Conversely, providing a 20%-SSD resulted in a drop of the  
188 prepupal weight of control animals that was significantly compensated in *Rheb<sup>++</sup>* and *PTEN-*  
189 *RNAi* prepupae (Figure 3A and 3B).

190 Next, we measured the total amounts of protein, triacylglycerol (TAG), glycogen and trehalose—  
191 the most abundant circulating sugar in *Drosophila*. Although variations in protein levels were

192 observed, none of them were statistically significant (Figure 3C). TAG levels in control prepupae  
193 were not affected by sucrose supplementation and did not vary in *PTEN-RNAi*, but were  
194 significantly decreased in *Rheb<sup>++</sup>* animals (Figure 3D). Feeding larvae a 20%-SSD since the  
195 L2/L3 molting transition resulted in a marked increase in glycogen and trehalose levels in  
196 control prepupae (Figure 3E-F). In *Rheb<sup>++</sup>* and, in lower extent, in *PTEN-RNAi* prepupae,  
197 glycogen levels were significantly lower than those measured in controls (Figure 3E). Finally,  
198 trehalose levels were strongly decreased in both *Rheb<sup>++</sup>* and *PTEN-RNAi* prepupae fed either a  
199 standard or a 20%-SSD as compared to the control (Figure 3F). Taken together, these findings  
200 suggest that a ubiquitous increased activity of either mTORC1 or mTORC2 provokes an  
201 apparent increase in metabolite consumption. This metabolic rate is correlated with a relative  
202 increase in body weight for larvae fed a 20%-SSD, but not for those fed a standard diet. We  
203 previously observed that increasing dietary sucrose induced a reduction in food intake [59] that  
204 may account for the body weight reduction of control animals. Potentially, food intake could be  
205 less affected in *Rheb<sup>++</sup>* and *PTEN-RNAi* animals, thereby leading to a compensatory effect on  
206 body weight. Measuring food intake in *Rheb<sup>++</sup>* or *PTEN-RNAi* larvae was not applicable since  
207 most of them die during larval stage and thus, terminate feeding earlier. In sum, our data  
208 indicates that basal metabolism is altered in the few *Rheb<sup>++</sup>* or *PTEN-RNAi* larvae that survive  
209 and further suggests that in most cases stronger metabolic disruption happened, resulting in  
210 lethal homeostatic defects.

211

## 212 **Knocking-down glycolysis at the whole body level**

213 Since manipulating mTOR resulted in a decrease in the levels of TAG and glycogen stores and  
214 of circulating trehalose (Figure 3), we asked whether the basal energetic metabolism affected  
215 mTOR signaling. First, we ubiquitously expressed interfering RNA against  
216 phosphofructokinase1 (*PFK1-RNAi*), pyruvate kinase (*PK-RNAi*) pyruvate dehydrogenase  
217 (*PDH-RNAi*) and lactate dehydrogenase (*LDH-RNAi*). PFK1 catalyzes the third glycolytic  
218 reaction to form fructose 1,6-bisphosphate; PK catalyzes the final glycolytic reaction to form

219 pyruvate; PDH directs the mitochondrial fate of pyruvate, whereas LDH directs its anaerobic fate  
220 (Figure 4A). When directed with the ubiquitous *da-gal4* driver, *PK-RNAi* provoked early larval  
221 lethality, *PFK1-RNAi* and *PDH-RNAi* provoked larval lethality at L2 or L3 stages, whereas *LDH-*  
222 *RNAi* induced a semi-lethal phenotype at larval or pupal stages (Figure 4B).

223 Second, to monitor mTOR activity following ubiquitous knockdown of glycolysis, the *da-gal4*  
224 driver was combined with a ubiquitous thermo-sensitive form of the Gal4 inhibitor, Gal80<sup>ts</sup> (*tub-*  
225 *gal80<sup>ts</sup>*) that blocks Gal4 activity at 21°C but not at 29°C, thereby allowing RNAi expression after  
226 temperature shift. Each RNAi was ubiquitously induced at early L1 stage and protein extracts  
227 were prepared two days later using late L2 larvae. At this stage the larvae were still viable,  
228 although those expressing PK-RNAi did not undergo L2/L3 transition and eventually died  
229 (Figure 4B). Western-blotting using these L2 protein extracts revealed that RNAi-knockdown of  
230 PFK1, LDH or PDH did not affect Akt or dS6K phosphorylation (Figure 4C). In contrast, PK  
231 knockdown strongly decreased dS6K phosphorylation and to a lower extent Akt phosphorylation  
232 (Figure 4C). These results indicate that mTORC1 signaling may be affected when knocking  
233 down PK, but not when knocking down any other enzyme directly linked to glycolysis.  
234 Nonetheless, the lethal phenotype of PK-RNAi larvae occurring at the late L2 stage (Figure 4B)  
235 might weaken the larvae, inducing a subsequent effect on mTOR signaling.

236 To evaluate the requirement of glycolysis for adult survival, RNAi-knockdown was induced by  
237 temperature shift to 29°C in newly emerged flies and lethality was counted every second day. In  
238 both males and females, PK and PFK1 knockdown provoked lethality between 10 to 14 days  
239 after temperature shift (Figure 4D). Knockdown of PDH and LDH also induced adult lethality,  
240 although not as soon as PK and PFK1 knockdown (Figure 4D). As a comparison, we analyzed  
241 FASN knockdown in adults; about a quarter of *FASN-RNAi* flies died between 10 to 14 days,  
242 while the others survived nearly as well as control flies (Figure 4D). Taken together, these data  
243 indicate that glycolysis is essential for both larval development and adult survival. However,  
244 prior to the appearance of the deleterious phenotype, glycolysis knockdown is unlikely to  
245 impinge on mTOR signaling.

246  
247 **Cell-autonomous requirement of glycolysis for mTORC2- but not mTORC1-dependent**  
248 **overgrowth**

249 To investigate the requirement of glycolysis to sustain mTOR-dependent growth at the cell-  
250 autonomous level, *PFK1-RNAi*, *PK-RNAi*, *PDH-RNAi* and *LDH-RNAi* were induced in *PTEN*<sup>-/-</sup> or  
251 *Rheb*<sup>+</sup> clones. Except a moderate effect of *PK-RNAi*, clones expressing interfering RNA against  
252 these metabolic enzymes did not significantly affect the growth of FB cells (Figure 5A-D and  
253 5M). In combined clones, none of the RNAi affected the growth of *Rheb*<sup>+</sup> clones (Figure 5E-H  
254 and 5M). In contrast, the size of *PTEN*<sup>-/-</sup> clones was significantly decreased when co-expressing  
255 RNA against any of these metabolic enzymes (Figure 5I-M). These findings indicate that both  
256 aerobic and anaerobic glycolysis are required to sustain mTORC2-dependent overgrowth at the  
257 cell-autonomous level. In contrast, reducing glycolysis does not counteract mTORC1-dependent  
258 overgrowth, suggesting the existence of compensatory pathways.

259  
260 **Effect of Lipogenesis on mTOR signaling**

261 Since glycolysis and FA synthesis are tightly connected metabolic pathways [59], we  
262 investigated whether lipogenesis affects mTOR signaling. FA synthesis is catalyzed by FASN  
263 (Figure 4A). The *Drosophila* genome encodes three *FASN* genes, *FASN1* is ubiquitously  
264 expressed but not *FASN2* or *FASN3* [60-62]. The deletion of the *FASN1* and *FASN2* tandem  
265 (*FASN*<sup>Δ24-23</sup> deletion, hereafter called *FASN*<sup>1-2</sup>) results in a lethal phenotype that can be rescued  
266 by feeding larvae a lipid-complemented diet (beySD) [59, 62]. We observed that beySD-rescued  
267 *FASN*<sup>1-2</sup> mutant larvae exhibited a delay in development, as measured by the duration of larval  
268 development to metamorphosis entry (Figure 6A). Further, when beySD-rescued *FASN*<sup>1-2</sup>  
269 mutant larvae were transferred at the L2/L3 larval transition onto a 10% sucrose-supplemented-  
270 beySD, only a few of them completed the third larval stage and, after an extreme developmental  
271 delay, entered metamorphosis (Figure 6A). Delay in development can be due to a default in

272 ecdysone production that results in giant pupae [63] or to impaired mTOR signaling that results  
273 in reduced body growth [54, 64]. Measurements of prepupal weight revealed that *FASN<sup>1-2</sup>*  
274 mutant prepupae exhibited a severe reduction in body weight, whether or not they were  
275 supplemented with sucrose (Figure 6B), suggesting a default in mTOR signaling. Therefore, we  
276 analyzed the phosphorylation of the *Drosophila* S6Kinase (dS6K) and Akt in protein extracts of  
277 late feeding L3 larvae. Western-blotting revealed that the dS6K protein resolved in several  
278 bands in *FASN<sup>1-2</sup>* extracts, whereas Akt protein was unchanged (Figure 6C). These results  
279 suggest that dS6K but not Akt might be degraded in the *FASN<sup>1-2</sup>* mutant background. In  
280 addition, dS6K phosphorylation decreased in *FASN<sup>1-2</sup>* extracts and became barely detectable  
281 when *FASN<sup>1-2</sup>* larvae were fed a sucrose-supplemented-beySD (Figure 6C). Conversely, the  
282 phosphorylation of Akt was unaffected in larvae fed a beySD, although it was slightly decreased  
283 in larvae fed a sucrose-supplemented-beySD (Figure 6C). This finding contrasts with our  
284 previous observation showing that FB explants of *FASN<sup>1-2</sup>* mutant larvae were hypersensitive to  
285 insulin [59]. However, *FASN<sup>1-2</sup>* mutants also exhibited a decrease in food intake [59], which  
286 might induce a systemic suppression of dS6K phosphorylation, while FB explant were cultured  
287 in nutrient media supplemented with insulin. Therefore, to determine whether *FASN* mutation  
288 affects mTOR signaling at the cell-autonomous level, we analyzed P-S6 and P-Akt in *FASN<sup>1-2</sup>*  
289 mutant clones in the FB. As for control clones, about half of the *FASN<sup>1-2</sup>* clonal cells were P-S6  
290 positive (Figure 2J and 2K). Furthermore, no effect on P-Akt was observed in *FASN<sup>1-2</sup>* clonal  
291 cells (Figure 2D). In summary, these findings reveal that disrupting FA synthesis does not  
292 significantly affect mTORC1 and mTORC2 signaling at the cell-autonomous level, although it  
293 seems to impinge on mTORC1 signaling when inhibited in the whole animal whether directly or  
294 indirectly.

295  
296 **Cell-autonomous requirement of FA synthesis for mTORC2- but not mTORC1-dependent**  
297 **overgrowth**

298 To determine, whether lipogenesis is required at the cell-autonomous level to sustain mTORC1  
299 and/or mTORC2 dependent growth, we analyzed *FASN*<sup>1-2</sup> clones while enhancing either of the  
300 mTOR signaling branch in FB cells. We previously reported [59] that *FASN*<sup>1-2</sup> clonal cells in the  
301 FB were slightly reduced in size and that this effect was dramatically increased in larvae fed a  
302 20%-SSD (Supplementary Figure S1 and Figure 7M). Therefore, we generated *PTEN*<sup>-/-</sup> and  
303 *Rheb*<sup>+</sup> clones combined or not with the *FASN*<sup>1-2</sup> mutation and analyzed them in the FB of larvae  
304 fed either a standard diet or a 20%-SSD. As compared to the standard diet, feeding larvae a  
305 20%-SSD had no effect on the size of *Rheb*<sup>+</sup> clonal cells, but significantly reduced the size of  
306 *PTEN*<sup>-/-</sup> and of *PTEN*<sup>-/-</sup>;*Rheb*<sup>+</sup> clonal cells (Figure 7A-F and 7M). Further, when combined with  
307 the *FASN*<sup>1-2</sup> mutation, *PTEN*<sup>-/-</sup> but not *Rheb*<sup>+</sup> clones were significantly reduced in size (Figure  
308 7G-H and 7M). The *FASN*<sup>1-2</sup> mutation also provoked a severe size reduction of *PTEN*<sup>-/-</sup>;*Rheb*<sup>+</sup>  
309 clones (Figure 7I and 7M). Moreover, as compared to the standard diet, feeding larvae a 20%-  
310 SSD induced a significant size reduction of *FASN*<sup>1-2</sup>;*Rheb*<sup>+</sup>, *FASN*<sup>1-2</sup>;*PTEN*<sup>-/-</sup> and *FASN*<sup>1-2</sup>;*PTEN*<sup>-/-</sup>;  
311 *Rheb*<sup>+</sup> clonal cells (Figure 7J-L and 7M). Of note, except for the *FASN*<sup>1-2</sup>;*Rheb*<sup>+</sup> clonal cells in  
312 larvae fed a 20%-SSD that exhibited a size roughly identical to that of the surrounding control  
313 cells (Figure 7J), the cell size was always bigger than the controls (Figure 7M). These findings  
314 indicate that, in larvae fed a standard diet, FA synthesis is at least in part required to sustain  
315 over-growth induced by mTORC2, but not mTORC1. They also reveal that additional dietary  
316 sucrose is rather detrimental for the growth of cells either deficient for FA synthesis or over-  
317 active for mTORC2, suggesting that these cells have a restricted homeostatic ability to adjust to  
318 an unbalanced diet, whereas mTORC1 activated cells at least in part maintain this ability.

319

## 320 **DISCUSSION**

321 In this study, we used the powerful *Drosophila* genetics to investigate the functional links  
322 between mTOR-dependent growth and the glycolytic/lipogenic axis. On one hand, we  
323 dampened this metabolic axis or enhanced mTORC1/2 activity in the whole organism to mimic  
324 the effect that might be induced by drug treatment with a systemic inhibitor. On the other hand,

325 to monitor the cell growth process that spans the entire developmental program at the cell-  
326 autonomous level, we analyzed clonal FB cells in mosaic animals. Intriguingly, our study reveals  
327 apparent contradictory effects between perturbations at the whole body and cell-autonomous  
328 levels.

329 At the organismal level, knockdown of glycolytic enzymes or deficiency of FASN result in animal  
330 lethality. However, *FASN<sup>1-2</sup>* mutant animals supplemented with dietary lipids can survive but  
331 exhibit a dramatic overall growth suppression. This growth defect might result from a decrease  
332 in mTORC1 activity that is strongly reduced in *FASN<sup>1-2</sup>* mutant animals, suggesting that  
333 mTORC1 but not mTORC2 signaling relies on lipogenesis. In contrast, at the cell autonomous  
334 level, the mutation of *FASN<sup>1-2</sup>* restrains mTORC2 but not mTORC1 dependent overgrowth in FB  
335 cells. These apparent contradictory findings, suggest that the growth defect and the reduction of  
336 mTORC1 activity in *FASN<sup>1-2</sup>* mutants are not due to the addition of cell-autonomous effects but  
337 rather to a systemic regulation. Potentially, FASN default might affect the activity of a specific  
338 tissue, as for instance, the neurosecretory cells that synthesize and secrete insulin like peptides,  
339 which promote systemic body growth [65]. Alternatively, considering that mTORC1 directly  
340 responds to nutrients [18-20], the drop of mTORC1 activity may be a consequence of feeding,  
341 since we previously reported a decrease in nutrient uptake in *FASN<sup>1-2</sup>* mutant animals [59].  
342 Consistently, a previous study on the transcription factor *mio* —the *Drosophila* homologue of  
343 *mondoA* and ChREBP that regulate the glycolytic/lipogenic axis in response to dietary sugar  
344 [66, 67]— suggests the existence of a FASN-dependent effect in the FB on the control of food  
345 intake [68]. FB-knockdown of *mio* results in the lack of sucrose-induced expression of *FASN1*  
346 and in a decrease in food intake. This study suggests that the FASN default perturbs body  
347 homeostasis and indirectly affects the neuronal control of feeding behavior. However, it does  
348 not exclude that a lipogenic defect in neuronal cells may also directly impinge on feeding  
349 behavior. Finally, the drop of mTORC1 activity observed in *FASN<sup>1-2</sup>* mutants may be a  
350 consequence of malonyl-CoA accumulation, since mTOR malonylation has been reported to  
351 inhibit mTORC1 but not mTORC2 activity [69]. Malonylation of mTOR may also account for the

352 size reduction of *FASN*<sup>1-2</sup> mutant cells over-expressing Rheb in animals fed a 20%-SSD,  
353 consistent with the increased expression of lipogenic enzymes induced by dietary sucrose [59].  
354 Thus, mTOR malonylation and the subsequent decrease in mTORC1 activity might occur only  
355 when interfering with a context of high demand for lipogenesis.

356 Our study reveals that over-activation of mTORC1 and to a lesser extent of mTORC2, results in  
357 a decrease in glycogen and TAG stores and in circulating trehalose, suggesting that mTOR  
358 activation enhances metabolite consumption to sustain cell growth. It is therefore surprising that  
359 activation of neither mTORC1 nor mTORC2 induces an increase in body weight. Nonetheless,  
360 overall body growth depends on an intricate regulatory network that integrates cell-autonomous  
361 effects and humoral messages. For instance, previous studies reported that mTOR activation  
362 within the ring gland, results in a systemic decrease in body growth [70-72]. Therefore, mTOR  
363 ubiquitous activation is likely to promote the growth of most cells but might concurrently perturb  
364 endocrine signals dampening overall growth. Of note, we observed that larvae fed a 20%-SSD  
365 result in pupae with reduced body weight, an effect that is partially suppressed when either of  
366 the mTORC-signaling branch is over-activated. The fact that the overall body weight of mTOR-  
367 stimulated animals is maintained within a range likely compatible with organismal survival  
368 contrasts with the observed high rate of lethality. The decrease in stores and circulating sugars  
369 suggests that in these animals each cell tends to increase its basal metabolism evoking an  
370 egoist behavior that might perturb the equilibrium between cell-autonomous and systemic  
371 regulation. Thus, in a stressful situation, as when animals are fed a 20%-SSD, the need of a  
372 tight adjustment to an unbalanced diet may enhance the distortion between cell-autonomous  
373 effects and systemic regulation, resulting in an increased rate of lethality.

374 In agreement with other studies [24, 49-52], we show that the mTORC1 and mTORC2 branches  
375 work independently in the *Drosophila* FB and we provide evidence that the previously described  
376 *mTOR*<sup>2L1</sup> mutation [54] affects mTORC1 signaling only. A plethora of studies in mammalian  
377 cells indicate that mTOR activation directs metabolism towards glucose consumption, storage  
378 and anabolism [32, 34, 35, 39, 41-43, 73]. Our study rather suggests that in the *Drosophila*



379 larvae, mTOR promotes metabolite consumption through glycolysis but not storage. However,  
380 at the cell-autonomous level, we observe that inhibition of lipogenesis or glycolysis restrains  
381 neither larval FB cell growth nor overgrowth induced by mTORC1 stimulation in these cells.  
382 These findings counteract the idea that mTORC1 potentiates a glycolytic/lipogenic axis [32] to  
383 sustain cell growth. To overcome the lack of glycolytic products and of membrane lipids, these  
384 cells may benefit of a transfer from neighboring cells and might favor alternative metabolic  
385 pathways, including glutamine catabolism to feed TCA anaplerosis which has been shown to be  
386 a crucial pathway in mTORC1-stimulated mammalian cells [36-38]. Nonetheless, such  
387 compensatory processes do not fully operate to sustain mTORC2-dependent overgrowth. In  
388 these cells, the mutation of PTEN results in mTORC2 hyper-activation and potentially impedes  
389 the ability to modulate this signaling branch. Therefore, it is tempting to speculate that the  
390 modulation of mTORC2 signaling at least in part contributes to the regulation of these  
391 compensatory processes.

392 As a coordinator of growth and metabolism, mTOR plays a central role in tumor development [7,  
393 74, 75]. PTEN, the tumor suppressor that counteracts PI3K activity upstream of mTORC2  
394 signaling, is deficient in several human cancers [30]. Mutation of TSC1 or TSC2, the essential  
395 subunits of the tuberous sclerosis complex, is associated with benign tumors but also with brain,  
396 kidney and lung destructive diseases [76]. To investigate the role of mTOR regarding tumor  
397 development, a recent study reported the generation of liver-specific double knockout mice for  
398 TSC1 and PTEN [77]. These mice develop hepatic steatosis that eventually progresses to  
399 hepatocellular carcinoma. Both processes are suppressed in mice fed the mTORC1/2 inhibitors  
400 INK128, but not the mTORC1 inhibitor rapamycin, supporting an mTORC2 specific effect. The  
401 combination of inhibitors against mTOR and metabolism is currently under clinical investigation  
402 to fight cancers [7]. Importantly, our study reveals that ubiquitous inhibition of basal metabolism  
403 produces dramatic effects during development, while it only moderates cell growth induced by  
404 mTOR over-activation. Therefore, the use of drug therapy to fight cancer must be taken with

405 caution, in particular if development is not complete and most efforts should be made to  
406 selectively target sick tissues.

407

## 408 **MATERIAL & METHODS**

### 409 **Genetics and fly handling**

410 Fly strains: *P[w[+mC]=tubP-GAL80]LL10,P[ry[+t7.2]=neoFRT]40A*, *daughterless(da)-gal4*, *tub-*  
411 *gal80<sup>ts</sup>*, *UAS-Dcr-2* (Bloomington Stock Center); *FASN<sup>1-2</sup>* [59]; *mTOR<sup>ΔP</sup>* [56]; *mTOR<sup>2L1</sup>* and  
412 *PTEN* [54]; *EP(UAS)-Rheb* [53]; ); inducible RNA-interfering (*UAS-RNAi*) lines to *PTEN* (NIG  
413 5671R-2), *FASN1* (VDRG 29349), *PFK1* (VDRG 3017), *PK* (VDRG 49533) *PDH* (VDRG 40410),  
414 *LDH* (VDRG 31192) [78]. The *Minute* stock used was previously referred to as *FRT40/P(arm-*  
415 *LacZ w<sup>+</sup>)* [79] but exhibit both developmental delay and short and slender bristles, typically  
416 reported as *Minute* phenotype [57]. To generate MARCM clones in the *Minute* background,  
417 these flies were recombined with the *P[w[+mC]=tubP-GAL80]LL10,P[ry[+t7.2]=neoFRT]40A*  
418 chromosome.

419 The standard media used in this study contained agar (1g), polenta (6g) and yeast (4g) for  
420 100ml. Lipid- (beySD) and sugar-complemented media were prepared as previously described  
421 [59].

422 To select *FASN<sup>1-2</sup>* mutant larvae, we used a GFP-labelled CyO balancer chromosome. Flies  
423 were let to lay eggs on grape juice plates for less than 24 hrs. Then, some beySD media was  
424 put in the middle of the plates; larvae that do not express GFP were collected the next day and  
425 transferred to fresh tubes. Prepupae were collected once a day to evaluate developmental delay  
426 and to measure body weight.

427

### 428 **Molecular biology and Biochemistry**

429 To test RNAi-knockdown efficacy to the glycolytic enzymes (Supplementary Figure S2), *UAS-*  
430 *Dcr-2;da-gal4,tub-gal80<sup>ts</sup>* virgin females were mated with *UAS-RNAi* males. Flies were let to lay

431 eggs overnight and tubes were kept at 19°C for two days. Tubes were then transferred at 29°C  
432 and two days later, larvae of roughly the same size were collected. Reverse transcription and  
433 quantitative PCR were performed as previously described [60].

434 Protein extracts for western-blotting were prepared as previously described [51]. Antibody used  
435 in for western-blotting have been previously described [51] or commercially provided for Akt  
436 (Cell signaling 4054).

437 For metabolic measurements, parental flies were let to lay eggs in tubes for less than 24 hrs at  
438 25°C. Tubes were then transferred at 29°C to strengthen the gal4/UAS effect, and using a *UAS-*  
439 *Dcr-2* to strengthen the RNAi effect. Larvae were either maintained in the same tubes or  
440 selected prior to L2/L3 transition and transferred on 20%-SSD. Collection of prepupae and  
441 metabolic measurements were performed as previously described [59].

442

#### 443 **Clonal analysis**

444 All the clones were generated using the MARCM strategy [80]. Parental flies were let to lay  
445 eggs at 25°C for seven hrs. Tubes were then heat shocked for 65 minutes in a water bath at  
446 38°C so that recombination happens while FB precursor cells are in dividing process. FB from  
447 feeding larvae at the end of the L3 stage where dissected, fixed, membranes were labelled with  
448 phalloidin and nuclei with DAPI, and FB were mounted as previously described [59]. Image  
449 acquisitions were obtained using a Leica SP8 confocal laser-scanning microscope. For immuno  
450 staining the phospho-S6 antibody has been previously described [58] and the phospho-Akt  
451 commercially provided (Cell signaling 4054). The cell size calculation have been performed as  
452 previously described [59] and correspond to a set of experiments that spanned a two-year  
453 period. It represent too many replicates, so that it was not possible to make them at the same  
454 time. Therefore, for the graphs of cell size measurement (Figure 2M, 5M and 6G), values are  
455 reused when they correspond to the same genotype and conditions. This allows a direct  
456 comparison between the experiments.

457

## 458 **Statistical analysis**

459 Statistical analyses were performed with R version 3.4.4, scripts are available on request.  
460 Significance for the statistical tests was coded in the following way based on the p-values: \*\*\*: 0  
461  $< p < 0.001$ ; \*\*:  $0.001 < p < 0.01$ ; \*:  $0.01 < p < 0.05$ . P-values were corrected for multiple testing  
462 by a Holm-Bonferroni method [81]. Clone sizes were analyzed with a mixed-effect linear model  
463 on the logarithm of cell area, considering the treatment (Genotype and Sucrose conditions) as a  
464 fixed effect and Series/Larva as random effects (Figures 1, 5, and 7, Supplementary Table S1).  
465 The reported effects (and the corresponding P-values) were obtained from the difference  
466 between the (log) area of marked clonal cells and that of control surrounding cells from the  
467 same treatment, by setting the appropriate contrast with the “multcomp” package [82], according  
468 to the pattern:  $EA,B = \log(MA) - \log(WA) - [\log(MB) - \log(WB)]$ , where EA,B is the difference  
469 between treatments (genotype and sucrose levels) A and B, MA and MB standing for the area  
470 of marked cells, and WA, WB for the area of control cells in those treatments. This is equivalent  
471 to testing whether marked/control cell area ratios differ between treatments. PS6+ clone  
472 frequencies were treated as binomial measurements in a mixed-effect generalized linear model  
473 “lme4” package [83], featuring Genotype as a fixed effect, and Series/Larva as random effects.  
474 Both datasets of pupal weights were analyzed independently with linear models including Sex,  
475 Genotype, and Sucrose level effects and all their interaction terms (Figure 3A-B and  
476 Supplementary Table S3 for PTEN knockdown and Rheb overexpression; and Figure 6B and  
477 Supplementary Table S4 for *FASN*<sup>1-2</sup> mutants). TAG, Protein, Glycogen, and Threolose  
478 concentrations were also analyzed with linear models involving Genotype, Sucrose level, and  
479 their interactions as fixed effects (Fig3 and Supplementary Table S3).

480

## 481 **ACKNOWLEDGMENTS**

482 We wish to thank D Petit for preparing the fly media, H Stocker for fly stocks, A Teleman for the  
483 phospho-S6 antibody, M Gettings for editing the manuscript, and the NIG and VDRC stock  
484 centers for RNAi fly strains.

485

## 486 REFERENCES

- 487 1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. *Cell*.  
488 2012;149(2):274-93. PubMed PMID: 22500797.
- 489 2. Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting  
490 anabolic metabolism. *Biochem Soc Trans*. 2013;41(4):906-12. PubMed PMID: 23863154.
- 491 3. Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. *Cell Metab*.  
492 2013;18(4):465-9. PubMed PMID: 23973332.
- 493 4. Caron A, Richard D, Laplante M. The Roles of mTOR Complexes in Lipid Metabolism.  
494 *Annu Rev Nutr*. 2015;35:321-48. PubMed PMID: 26185979.
- 495 5. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and  
496 signalling crosstalk. *Nat Rev Mol Cell Biol*. 2014;15(3):155-62. PubMed PMID: 24556838.
- 497 6. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. *Cell*.  
498 2017;168(6):960-76. doi: 10.1016/j.cell.2017.02.004. PubMed PMID: 28283069; PubMed  
499 Central PMCID: PMC5394987.
- 500 7. Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual  
501 determinants in cancer. *Nat Rev Cancer*. 2018;18(12):744-57. Epub 2018/11/15. doi:  
502 10.1038/s41568-018-0074-8. PubMed PMID: 30425336.
- 503 8. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR  
504 interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth  
505 machinery. *Cell*. 2002;110(2):163-75. PubMed PMID: 12150925.
- 506 9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of  
507 Akt/PKB by the rictor-mTOR complex. *Science*. 2005;307(5712):1098-101. PubMed PMID:  
508 15718470.

- 509 10. Ugur B, Chen K, Bellen HJ. Drosophila tools and assays for the study of human diseases.  
510 Dis Model Mech. 2016;9(3):235-44. doi: 10.1242/dmm.023762. PubMed PMID: 26935102;  
511 PubMed Central PMCID: PMC4833332.
- 512 11. Montagne J, Radimerski T, Thomas G. Insulin signaling: lessons from the Drosophila  
513 tuberous sclerosis complex, a tumor suppressor. Sci STKE. 2001;2001(105):PE36.  
514 PubMed PMID: 11675514.
- 515 12. Padmanabha D, Baker KD. Drosophila gains traction as a repurposed tool to investigate  
516 metabolism. Trends Endocrinol Metab. 2014;25(10):518-27. doi:  
517 10.1016/j.tem.2014.03.011. PubMed PMID: 24768030.
- 518 13. Antikainen H, Driscoll M, Haspel G, Dobrowolski R. TOR-mediated regulation of  
519 metabolism in aging. Aging Cell. 2017;16(6):1219-33. doi: 10.1111/accel.12689. PubMed  
520 PMID: 28971552; PubMed Central PMCID: PMC5676073.
- 521 14. Wangler MF, Hu Y, Shulman JM. Drosophila and genome-wide association studies: a  
522 review and resource for the functional dissection of human complex traits. Dis Model Mech.  
523 2017;10(2):77-88. doi: 10.1242/dmm.027680. PubMed PMID: 28151408; PubMed Central  
524 PMCID: PMC5312009.
- 525 15. Lehmann M. Endocrine and physiological regulation of neutral fat storage in Drosophila.  
526 Mol Cell Endocrinol. 2018;461:165-77. doi: 10.1016/j.mce.2017.09.008. PubMed PMID:  
527 28893568; PubMed Central PMCID: PMC5756521.
- 528 16. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev  
529 Mol Cell Biol. 2009;10(5):307-18. PubMed PMID: 19339977.
- 530 17. Goberdhan DC, Ogmundsdottir MH, Kazi S, Reynolds B, Visvalingam SM, Wilson C, et al.  
531 Amino acid sensing and mTOR regulation: inside or out? Biochem Soc Trans. 2009;37(Pt  
532 1):248-52. PubMed PMID: 19143641.
- 533 18. Groenewoud MJ, Zwartkuis FJ. Rheb and mammalian target of rapamycin in mitochondrial  
534 homeostasis. Open Biol. 2013;3(12):130185. PubMed PMID: 24352740.
- 535 19. Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with  
536 biosynthetic output. Nat Cell Biol. 2013;15(6):555-64. PubMed PMID: 23728461.

- 537 20. Montagne J. A Wacky Bridge to mTORC1 Dimerization. *Dev Cell*. 2016;36(2):129-30.  
538 PubMed PMID: 26812011.
- 539 21. Yang H, Jiang X, Li B, Yang HJ, Miller M, Yang A, et al. Mechanisms of mTORC1 activation  
540 by RHEB and inhibition by PRAS40. *Nature*. 2017;552(7685):368-73. Epub 2017/12/14.  
541 doi: 10.1038/nature25023. PubMed PMID: 29236692; PubMed Central PMCID:  
542 PMC5750076.
- 543 22. Montagne J, Thomas G. S6K integrates nutrient and mitogen signals to control cell growth.  
544 . In: Hall M, Raff, M., Thomas, G., editor. *Cell growth: control of cell size*.  
545 ed: Cold Spring Harbor Press; 2004. p. 265-98.
- 546 23. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase  
547 (S6K) within mTOR signalling networks. *Biochem J*. 2012;441(1):1-21. PubMed PMID:  
548 22168436.
- 549 24. Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G. Lethality of *Drosophila*  
550 lacking TSC tumor suppressor function rescued by reducing dS6K signaling. *Genes Dev*.  
551 2002;16(20):2627-32. PubMed PMID: 12381661.
- 552 25. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Rocco M, Stocker H, et al. Insulin  
553 activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.  
554 *Mol Cell*. 2003;11(6):1457-66. PubMed PMID: 12820960.
- 555 26. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and  
556 regulates mTOR signaling. *Genes Dev*. 2003;17(15):1829-34. doi: 10.1101/gad.1110003.  
557 PubMed PMID: 12869586; PubMed Central PMCID: PMC196227.
- 558 27. Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, et al. TBC1D7 is a third subunit  
559 of the TSC1-TSC2 complex upstream of mTORC1. *Mol Cell*. 2012;47(4):535-46. doi:  
560 10.1016/j.molcel.2012.06.009. PubMed PMID: 22795129; PubMed Central PMCID:  
561 PMC3693578.
- 562 28. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as  
563 regulators of growth and metabolism. *Nat Rev Genet*. 2006;7(8):606-19. doi:  
564 10.1038/nrg1879. PubMed PMID: 16847462.

- 565 29. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor  
566 signalling. *Nat Rev Mol Cell Biol.* 2018;19(1):31-44. doi: 10.1038/nrm.2017.89. PubMed  
567 PMID: 28974775; PubMed Central PMCID: PMC5894887.
- 568 30. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an  
569 integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer.* 2006;6(3):184-92. doi:  
570 10.1038/nrc1819. PubMed PMID: 16453012.
- 571 31. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. *Curr Opin Cell Biol.*  
572 2017;45:62-71. doi: 10.1016/j.ceb.2017.02.007. PubMed PMID: 28343126; PubMed Central  
573 PMCID: PMC5482768.
- 574 32. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a  
575 metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell.*  
576 2010;39(2):171-83. PubMed PMID: 20670887.
- 577 33. Polak P, Cybulski N, Feige JN, Auwerx J, Ruegg MA, Hall MN. Adipose-specific knockout  
578 of raptor results in lean mice with enhanced mitochondrial respiration. *Cell Metab.*  
579 2008;8(5):399-410. doi: 10.1016/j.cmet.2008.09.003. PubMed PMID: 19046571.
- 580 34. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR  
581 complex 1 regulates lipin 1 localization to control the SREBP pathway. *Cell.*  
582 2011;146(3):408-20. doi: 10.1016/j.cell.2011.06.034. PubMed PMID: 21816276; PubMed  
583 Central PMCID: PMC3336367.
- 584 35. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth  
585 and survival. *Cell.* 2003;115(5):577-90. PubMed PMID: 14651849.
- 586 36. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, et al. Glucose  
587 addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic  
588 demand with supply. *Mol Cell.* 2010;38(4):487-99. doi: 10.1016/j.molcel.2010.05.007.  
589 PubMed PMID: 20513425; PubMed Central PMCID: PMC2896794.
- 590 37. Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I, et al. The mTORC1/S6K1 pathway  
591 regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.



- 592 Curr Biol. 2014;24(19):2274-80. doi: 10.1016/j.cub.2014.08.007. PubMed PMID: 25220053;  
593 PubMed Central PMCID: PMCPMC4190129.
- 594 38. Csibi A, Fendt SM, Li C, Pouligiannis G, Choo AY, Chapski DJ, et al. The mTORC1  
595 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell.  
596 2013;153(4):840-54. doi: 10.1016/j.cell.2013.04.023. PubMed PMID: 23663782; PubMed  
597 Central PMCID: PMCPMC3684628.
- 598 39. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates  
599 the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J  
600 Biol Chem. 2005;280(37):32081-9. doi: 10.1074/jbc.M502876200. PubMed PMID:  
601 16027121.
- 602 40. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and  
603 oncogenesis. Semin Cancer Biol. 2009;19(1):25-31. doi: 10.1016/j.semcancer.2008.11.010.  
604 PubMed PMID: 19130886; PubMed Central PMCID: PMCPMC2814453.
- 605 41. Jaldin-Fincati JR, Pavarotti M, Frendo-Cumbo S, Bilan PJ, Klip A. Update on GLUT4  
606 Vesicle Traffic: A Cornerstone of Insulin Action. Trends Endocrinol Metab. 2017;28(8):597-  
607 611. doi: 10.1016/j.tem.2017.05.002. PubMed PMID: 28602209.
- 608 42. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early  
609 apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and  
610 mitochondrial hexokinase. Genes Dev. 2001;15(11):1406-18. doi: 10.1101/gad.889901.  
611 PubMed PMID: 11390360; PubMed Central PMCID: PMCPMC312709.
- 612 43. Houddane A, Bultot L, Novellademunt L, Johanns M, Gueuning MA, Vertommen D, et al.  
613 Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and  
614 protein synthesis in mitogen-stimulated thymocytes. Cell Signal. 2017;34:23-37. doi:  
615 10.1016/j.cellsig.2017.02.019. PubMed PMID: 28235572.
- 616 44. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr)  
617 confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest.  
618 2001;108(9):1359-67. doi: 10.1172/JCI12876. PubMed PMID: 11696581; PubMed Central  
619 PMCID: PMCPMC209440.

- 620 45. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that  
621 phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.  
622 EMBO J. 2005;24(8):1571-83. doi: 10.1038/sj.emboj.7600633. PubMed PMID: 15791206;  
623 PubMed Central PMCID: PMC1142569.
- 624 46. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, et al. Hexokinase-  
625 mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or  
626 absence of Bax and Bak. Mol Cell. 2004;16(5):819-30. doi: 10.1016/j.molcel.2004.11.014.  
627 PubMed PMID: 15574336.
- 628 47. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. Hepatic mTORC2  
629 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab.  
630 2012;15(5):725-38. doi: 10.1016/j.cmet.2012.03.015. PubMed PMID: 22521878.
- 631 48. Yuan M, Pino E, Wu L, Kacergis M, Soukas AA. Identification of Akt-independent regulation  
632 of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol Chem.  
633 2012;287(35):29579-88. doi: 10.1074/jbc.M112.386854. PubMed PMID: 22773877;  
634 PubMed Central PMCID: PMC3436168.
- 635 49. Radimerski T, Montagne J, Rintelen F, Stocker H, van der Kaay J, Downes CP, et al. dS6K-  
636 regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol.  
637 2002;4(3):251-5. PubMed PMID: 11862217.
- 638 50. Dong J, Pan D. Tsc2 is not a critical target of Akt during normal Drosophila development.  
639 Genes Dev. 2004;18(20):2479-84. PubMed PMID: 15466161.
- 640 51. Montagne J, Lecerf C, Parvy JP, Bennion JM, Radimerski T, Ruhf ML, et al. The nuclear  
641 receptor DHR3 modulates dS6 kinase-dependent growth in Drosophila. PLoS Genet.  
642 2010;6:e1000937. PubMed PMID: 20463884.
- 643 52. Pallares-Cartes C, Cakan-Akdogan G, Teleman AA. Tissue-specific coupling between  
644 insulin/IGF and TORC1 signaling via PRAS40 in Drosophila. Dev Cell. 2012;22(1):172-82.  
645 doi: 10.1016/j.devcel.2011.10.029. PubMed PMID: 22264732.

- 646 53. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, et al. Rheb is an  
647 essential regulator of S6K in controlling cell growth in *Drosophila*. *Nat Cell Biol.*  
648 2003;5(6):559-65. PubMed PMID: 12766775.
- 649 54. Oldham S, Montagne J, Radimerski T, Thomas G, Hafen E. Genetic and biochemical  
650 characterization of dTOR, the *Drosophila* homolog of the target of rapamycin. *Genes Dev.*  
651 2000;14(21):2689-94. PubMed PMID: 11069885.
- 652 55. Edgar BA, Orr-Weaver TL. Endoreplication cell cycles: more for less. *Cell.*  
653 2001;105(3):297-306. PubMed PMID: 11348589.
- 654 56. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. Regulation of cellular growth by the  
655 *Drosophila* target of rapamycin dTOR. *Genes Dev.* 2000;14(21):2712-24. PubMed PMID:  
656 11069888.
- 657 57. Morata G, Ripoll P. Minutes: mutants of *drosophila* autonomously affecting cell division rate.  
658 *Dev Biol.* 1975;42(2):211-21. PubMed PMID: 1116643.
- 659 58. Romero-Pozuelo J, Demetriades C, Schroeder P, Teleman AA. CycD/Cdk4 and  
660 Discontinuities in Dpp Signaling Activate TORC1 in the *Drosophila* Wing Disc. *Dev Cell.*  
661 2017;42(4):376-87 e5. doi: 10.1016/j.devcel.2017.07.019. PubMed PMID: 28829945.
- 662 59. Garrido D, Rubin T, Poidevin M, Maroni B, Le Rouzic A, Parvy JP, et al. Fatty Acid  
663 Synthase Cooperates with Glyoxalase 1 to Protect against Sugar Toxicity. *PLoS Genet.*  
664 2015;11(2):e1004995. PubMed PMID: 25692475.
- 665 60. Parvy JP, Napal L, Rubin T, Poidevin M, Perrin L, Wicker-Thomas C, et al. *Drosophila*  
666 *melanogaster* Acetyl-CoA-carboxylase sustains a fatty acid-dependent remote signal to  
667 waterproof the respiratory system. *PLoS Genet.* 2012;8(8):e1002925. PubMed PMID:  
668 22956916.
- 669 61. Chung H, Loehlin DW, Dufour HD, Vaccarro K, Millar JG, Carroll SB. A single gene affects  
670 both ecological divergence and mate choice in *Drosophila*. *Science.* 2014;343(6175):1148-  
671 51. PubMed PMID: 24526311.

- 672 62. Wicker-Thomas C, Garrido D, Bontonou G, Napal L, Mazuras N, Denis B, et al. Flexible  
673 origin of hydrocarbon/pheromone precursors in *Drosophila melanogaster*. *J Lipid Res*.  
674 2015;56(11):2094-101. PubMed PMID: 26353752.
- 675 63. Parvy JP, Wang P, Garrido D, Maria A, Blais C, Poidevin M, et al. Forward and feedback  
676 regulation of cyclic steroid production in *Drosophila melanogaster*. *Development*.  
677 2014;141(20):3955-65. PubMed PMID: 25252945.
- 678 64. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. *Drosophila* S6  
679 kinase: a regulator of cell size. *Science*. 1999;285(5436):2126-9. PubMed PMID:  
680 10497130.
- 681 65. Rulifson EJ, Kim SK, Nusse R. Ablation of insulin-producing neurons in flies: growth and  
682 diabetic phenotypes. *Science*. 2002;296(5570):1118-20. PubMed PMID: 12004130.
- 683 66. Mattila J, Havula E, Suominen E, Teesalu M, Surakka I, Hynynen R, et al. Mondo-Mix  
684 Mediates Organismal Sugar Sensing through the Gli-Similar Transcription Factor  
685 Sugarbabe. *Cell Rep*. 2015;13(2):350-64. PubMed PMID: 26440885.
- 686 67. Richards P, Ourabah S, Montagne J, Burnol AF, Postic C, Guilmeau S. MondoA/ChREBP:  
687 The usual suspects of transcriptional glucose sensing; Implication in pathophysiology.  
688 *Metabolism*. 2017;70:133-51. doi: 10.1016/j.metabol.2017.01.033. PubMed PMID:  
689 28403938.
- 690 68. Sassu ED, McDermott JE, Keys BJ, Esmaili M, Keene AC, Birnbaum MJ, et al.  
691 Mio/dChREBP coordinately increases fat mass by regulating lipid synthesis and feeding  
692 behavior in *Drosophila*. *Biochem Biophys Res Commun*. 2012;426(1):43-8. doi:  
693 10.1016/j.bbrc.2012.08.028. PubMed PMID: 22910416; PubMed Central PMCID:  
694 PMC3445662.
- 695 69. Bruning U, Morales-Rodriguez F, Kalucka J, Goveia J, Taverna F, Queiroz KCS, et al.  
696 Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation.  
697 *Cell Metab*. 2018;28(6):866-80 e15. Epub 2018/08/28. doi: 10.1016/j.cmet.2018.07.019.  
698 PubMed PMID: 30146486.

- 699 70. Caldwell PE, Walkiewicz M, Stern M. Ras activity in the *Drosophila* prothoracic gland  
700 regulates body size and developmental rate via ecdysone release. *Curr Biol*.  
701 2005;15(20):1785-95. PubMed PMID: 16182526.
- 702 71. Colombani J, Bianchini L, Layalle S, Pondeville E, Dauphin-Villemant C, Antoniewski C, et  
703 al. Antagonistic actions of ecdysone and insulins determine final size in *Drosophila*.  
704 *Science*. 2005;310(5748):667-70. PubMed PMID: 16179433.
- 705 72. Mirth C. Ecdysteroid control of metamorphosis in the differentiating adult leg structures of  
706 *Drosophila melanogaster*. *Dev Biol*. 2005;278(1):163-74. PubMed PMID: 15649469.
- 707 73. Wiperman MF, Montrose DC, Gotto AM, Jr., Hajjar DP. Mammalian Target of Rapamycin:  
708 A Metabolic Rheostat for Regulating Adipose Tissue Function and Cardiovascular Health.  
709 *Am J Pathol*. 2019;189(3):492-501. Epub 2019/02/26. doi: 10.1016/j.ajpath.2018.11.013.  
710 PubMed PMID: 30803496.
- 711 74. Harachi M, Masui K, Okamura Y, Tsukui R, Mischel PS, Shibata N. mTOR Complexes as a  
712 Nutrient Sensor for Driving Cancer Progression. *Int J Mol Sci*. 2018;19(10). Epub  
713 2018/10/24. doi: 10.3390/ijms19103267. PubMed PMID: 30347859.
- 714 75. Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor  
715 Targeting Therapy. *Int J Mol Sci*. 2019;20(3). Epub 2019/02/14. doi: 10.3390/ijms20030755.  
716 PubMed PMID: 30754640; PubMed Central PMCID: PMC6387042.
- 717 76. Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis  
718 complex. *Nat Rev Dis Primers*. 2016;2:16035. doi: 10.1038/nrdp.2016.35. PubMed PMID:  
719 27226234.
- 720 77. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. mTORC2 Promotes  
721 Tumorigenesis via Lipid Synthesis. *Cancer Cell*. 2017;32(6):807-23 e12. doi:  
722 10.1016/j.ccell.2017.11.011. PubMed PMID: 29232555.
- 723 78. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, et al. A genome-wide  
724 transgenic RNAi library for conditional gene inactivation in *Drosophila*. *Nature*.  
725 2007;448(7150):151-6. PubMed PMID: 17625558.

- 726 79. Bohni R, Riesgo-Escovar J, Oldham S, Brogiolo W, Stocker H, Andruss BF, et al.  
727 Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate  
728 IRS1-4. *Cell*. 1999;97(7):865-75. PubMed PMID: 10399915.
- 729 80. Lee T, Luo L. Mosaic analysis with a repressible cell marker (MARCM) for Drosophila  
730 neural development. *Trends Neurosci*. 2001;24(5):251-4. PubMed PMID: 11311363.
- 731 81. Holm S. A simple sequentially rejective multiple test procedure. *Scand J Statist*. 1079;6(65-  
732 70).
- 733 82. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biom*  
734 *J*. 2008;50(3):346-63. Epub 2008/05/16. doi: 10.1002/bimj.200810425. PubMed PMID:  
735 18481363.
- 736 83. Bates D, Mächler M, Bolker BM, Walker S. Fitting Linear Mixed-Effects Models Using lme4.  
737 *Journal of Statistical Software*. 2015;67(1):1-48. doi: 10.18637/jss.v067.i01.

738

## 739 **FIGURE LEGENDS**

740 **Figure 1: mTORC1 and mTORC2 dependent growth in FB cells. (A-L)** MARCM clones  
741 labeled by GFP (green) in the FB of L3 larvae. Nuclei were labeled with DAPI (silver) and  
742 membranes with phalloidin (red). Control (A), *Rheb*<sup>+</sup> (B), *PTEN*<sup>-/-</sup> (C) and *PTEN*<sup>-/-</sup>;*Rheb*<sup>+</sup> (D)  
743 clones were generated in a wild type background. *Rheb*<sup>+</sup> (E), *PTEN*<sup>-/-</sup> (F), *mTOR*<sup>2L1</sup> (G)  
744 *mTOR*<sup>2L1</sup>, *Rheb*<sup>+</sup> (H) *mTOR*<sup>2L1</sup>,*PTEN*<sup>-/-</sup> (I), *mTOR*<sup>ΔP</sup> (J), *mTOR*<sup>ΔP</sup>,*Rheb*<sup>+</sup> (K) and *mTOR*<sup>ΔP</sup>,*PTEN*<sup>-/-</sup>  
745 <sup>-</sup> (L) clones were generated in a *Minute* (*M*) background. Scale bars: 50μm. **(M)** Relative size of  
746 control (Co), *Rheb*<sup>+</sup>, *PTEN*<sup>-/-</sup>, and *PTEN*<sup>-/-</sup>;*Rheb*<sup>+</sup> clonal cells generated in a wild type  
747 background.

748

749 **Figure 2: mTORC1 and mTORC2 activity in FB cells. (A-J)** MARCM clones labeled by GFP  
750 (green) in the FB of L3 larvae. Clones were generated in a wild type (A,D,E,H,I,J) or a *Minute*  
751 (B,C,F,G) background and nuclei were labeled with DAPI (silver). FB tissues with *PTEN*<sup>-/-</sup> (A),

752 *mTOR<sup>ΔP</sup>* (B), *mTOR<sup>2L1</sup>* (C) and *FASN<sup>1-2</sup>* (J) clones were stained with a phospho-AKT antibody.  
753 FB tissues with control (D), *mTOR<sup>ΔP</sup>* (E), *mTOR<sup>2L1</sup>* (F) *Rheb<sup>+</sup>* (G), *PTEN<sup>-/-</sup>* (H) and *FASN<sup>1-2</sup>* (I)  
754 clones were stained with a phospho-S6 antibody. Scale bars: 50μm. (K) Percentage of P-S6  
755 positive clones with respect to the total number of MARCM clones for control, *FASN<sup>1-2</sup>*, *PTEN<sup>-/-</sup>*,  
756 *Rheb<sup>+</sup>*, *mTOR<sup>2L1</sup>* and *mTOR<sup>ΔP</sup>* genotypes.

757  
758 **Figure 3: Enhanced mTORC1 or mTORC2 signaling affects larval metabolism. (A-B)** Body  
759 weight of female (A) and male (B) prepupae formed from larvae fed either a standard (0%) or a  
760 20%-SSD (20%) as from the L2/L3 transition. (C-F) Measurement of total protein (C), TAG (D),  
761 glycogen (E) and trehalose (F) levels in prepupae fed either a standard or a 20%-SSD.  
762 Prepupae used in these measurements were the F1 progeny from *da-gal4* virgin females mated  
763 to either control (Co), *EP(UAS)-Rheb* (*Rheb<sup>++</sup>*) or *UAS-PTEN-RNAi* (*PTEN-Ri*) males.

764  
765 **Figure 4: Glycolysis knockdown in whole organisms. (A)** Scheme of basal metabolism.  
766 Glucose and trehalose enter glycolysis as glucose-6P, whereas fructose follows a distinct  
767 pathway to triose-P. Enzymes investigated in the present study are marked in red. (B)  
768 Phenotype of ubiquitous RNAi knockdown of PFK1, PK, LDH and PDH. Flies were left to lay  
769 eggs overnight either at 29°C (column 0h) or at 19°C and transferred to 29°C the day after  
770 (column 24h); then development proceeded at 29°C (i.e. the temperature that inactivates  
771 Gal80). (C) Western-blot analysis of total (top) or phosphorylated (mid) dS6K (left) or Akt (right)  
772 proteins; tubulin (bottom) was used as a loading control. Protein extracts were prepared with  
773 late L2 control larvae (Co) or L2 larvae expressing RNAi against the indicated metabolic  
774 enzymes. (E-F) Survival at 29°C of male (top) and female (bottom) control flies or flies  
775 expressing RNAi against the indicated metabolic enzymes as from adult eclosion.

776

777 **Figure 5: Cell-autonomous requirement of glycolytic enzymes for mTOR-dependent**  
778 **overgrowth. (A-G)** MARCM clones labeled by GFP (green) in the FB of L3 larvae. Nuclei were  
779 labeled with DAPI (silver) and membranes with phalloidin (red). Genotypes of MARCM clones  
780 are: *PFK1-RNAi* (A), *PK-RNAi* (B), *LDH-RNAi* (C), *PDH-RNAi* (D), *Rheb<sup>+</sup>,PFK1-RNAi* (E),  
781 *Rheb<sup>+</sup>,PK-RNAi* (F), *Rheb<sup>+</sup>,LDH-RNAi* (G), *Rheb<sup>+</sup>,PDH-RNAi* (H), *PTEN<sup>-/-</sup>;PFK1-RNAi* (I),  
782 *PTEN<sup>-/-</sup>;PK-RNAi* (J), *PTEN<sup>-/-</sup>;PDH-RNAi* (K) and *PTEN<sup>-/-</sup>;PDH-RNAi* (L). Scale bars: 50µm. **(M)**  
783 Relative size of clonal cells corresponding to the clones shown in A-L, and in Figure 2A for  
784 control (Co).

785  
786 **Figure 6: *FASN<sup>1-2</sup>* mutation affects developmental growth and mTOR signaling. (A)**  
787 Developmental duration from egg laying to metamorphosis onset of *w<sup>1118</sup>* control (Co) and  
788 *FASN<sup>1-2</sup>* (*FASN*) larvae fed either a beySD (0%) or a 10% sucrose-supplemented-beySD as  
789 from the L2/L3 transition (10%); n: total number of larvae collected for each condition. **(B)**  
790 Prepupal weight of females (left) and males (right) as listed in 4A; the numbers of weighted  
791 prepupae are indicated above each sample. **(C)** Western-blot analysis of (from top to bottom)  
792 total dS6K, phosphorylated dS6K, total Akt, phosphorylated Akt and total tubulin as a loading  
793 control. Protein extracts were prepared from feeding L3 larvae prior to the wandering stage as  
794 listed in 4A. For each condition, at least 30 larvae were used to prepare protein extracts.

795  
796 **Figure 7: Cell-autonomous requirement of *FASN* activity for mTOR-dependent**  
797 **overgrowth. (A-L)** MARCM clones labeled by GFP (green) in the FB of L3 larvae fed either a  
798 standard (A-C, G-I) or a 20%-SSD (D-E, J-L). Nuclei were labeled with DAPI (silver) and  
799 membranes with phalloidin (red). Genotypes of MARCM clones are: *Rheb<sup>+</sup>* (A,D), *PTEN<sup>-/-</sup>* (B,E)  
800 *PTEN<sup>-/-</sup>,Rheb<sup>+</sup>* (C,F), *FASN<sup>1-2</sup>;Rheb<sup>+</sup>* (G,J) *FASN<sup>1-2</sup>,PTEN<sup>-/-</sup>* (H,K) and the *FASN<sup>1-2</sup>,PTEN<sup>-/-</sup>*  
801 *;Rheb<sup>+</sup>* (I,L). Scale bars: 50µm. **(M)** Relative size of clonal cells corresponding to the clones  
802 shown in A-L and in supplementary Fig S1 for *FASN<sup>1-2</sup>* and Figure 1A for control (Co).



803

## 804 **SUPPORTING INFORMATIONS**

805 **S1 Table. Statistical tests corresponding to figures 1M (A), 5M (B), and 7M (C).** The model  
806 tests for the difference is the log ratio of *GFP<sup>+</sup>/GFP-surrounding* cells between pairs of  
807 genotypes (Co = control), accounting for larvae and series random effects (see the Methods  
808 section). P-values were corrected for multiple testing (Holm-Bonferroni method) and quantify the  
809 risk of rejecting the true null hypothesis at the table level.

810

811 **S2 Table. Statistical test of the difference in frequency between MARCM clones to**  
812 **control.** The model is a mixed effect, generalized linear model considering frequencies as  
813 binomial data and genotype as a fixed effect, while larvae / series were random effects. P-  
814 values were adjusted for multiple testing by a Holm-Bonferroni correction.

815

816 **S3 Table. Statistical tests corresponding to Figure 3.** Differences in male (A) or female (B)  
817 weight, in protein (C), in TAG (D), in glycogen (E) and in trehalose (F) between control (Co) and  
818 prepupae that ubiquitously express either Rheb (*Rheb<sup>++</sup>*) or an RNAi to PTEN (*PTEN<sup>i</sup>*). The  
819 column at the right indicates P-values corrected for multiple testing (Holm-Bonferoni correction).

820

821 **S4 Table. Statistical tests corresponding to Figure 6B.** Prepupal weight differences in males  
822 and females (Estimate and standard error, in mg) between control (*w*) and *FASN<sup>1-2</sup>* animals fed  
823 either a standard (0%) or a sucrose enriched diet (10%). The **Pr** column (right) indicates P-  
824 values corrected for multiple testing (Holm-Bonferoni correction).

825

826 **S1 Fig. Effect of dietary sugar on *FASN*<sup>1-2</sup> mutant cells.** *FASN*<sup>1-2</sup> MARCM clones labeled by  
827 GFP (green) in the FB of L3 larvae fed either a standard (A) or a 20%-SSD (B). Nuclei are  
828 labeled with DAPI (silver) and membranes by phalloidin (red). Scale bars: 50µm.

829  
830 **S2 Fig. Knockdown efficacy of the RNAi to the glycolytic enzymes.** (A) mRNA expression  
831 in control larvae (blue bars, +/- standard error) was adjusted to 100. mRNA levels after RNAi  
832 knockdown (red bars, +/- standard error) was calculated as a percentage of corresponding  
833 expression in control larvae. (B) Oligonucleotides used in RT-Q-PCR for each glycolytic  
834 enzyme.

835

bioRxiv preprint first posted online Apr. 11, 2019; doi: <https://doi.org/10.1101/006999>; The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Figure 1




Figure 2




Figure 3







Figure 5


**A**



**B**



**C**



bioRxiv preprint first posted online Apr. 11, 2019; doi: <http://dx.doi.org/10.1101/606699>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.






Figure 7





**B**

bioRxiv preprint first posted online Apr. 11, 2019; doi: <http://dx.doi.org/10.1101/606699>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/).

19°C >> 29°C	0h	24h
PFK1-Ri	† L1/L2	† late L2
PK-Ri	† L2/L3	† L3/pp
LDH-Ri	† L2/L3	† L3/pp
PDH-Ri	½† L3/pp	½† L3/pp





Figure 4